Discussed briefly in this New England Journal of M
Post# of 148177
(Total Views: 1313)
Posted On: 04/24/2020 12:18:27 PM
Discussed briefly in this New England Journal of Medicine Article excerpt today.
“ Six severely ill patients received the CCR5 inhibitor leronlimab (PRO 140, CytoDyn) on a compassionate-use basis, and 2 received the interleukin-6 receptor antagonist tocilizumab. Interleukin-6 levels were very elevated (range, 83 to 8175 pg per milliliter) when leronlimab was initiated (on day 0) in the 5 patients with elevated interleukin-6 levels; these levels decreased markedly 3 days later (range, 37 to 2022 pg per milliliter) (see Table S2 in the Supplementary Appendix).”
https://www.nejm.org/doi/full/10.1056/NEJMc2011117
“ Six severely ill patients received the CCR5 inhibitor leronlimab (PRO 140, CytoDyn) on a compassionate-use basis, and 2 received the interleukin-6 receptor antagonist tocilizumab. Interleukin-6 levels were very elevated (range, 83 to 8175 pg per milliliter) when leronlimab was initiated (on day 0) in the 5 patients with elevated interleukin-6 levels; these levels decreased markedly 3 days later (range, 37 to 2022 pg per milliliter) (see Table S2 in the Supplementary Appendix).”
https://www.nejm.org/doi/full/10.1056/NEJMc2011117
(12)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼